Teva planned for second generic Copaxone to enter market in 2018


Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018. TEL AVIV: Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018.



from Biotech News